Spondyloarthropathies
Conference Coverage
WCD: Secukinumab shows effectiveness for nail, palmoplantar psoriasis
Key clinical point: Two phase IIIb trials show secukinumab at 300 mg is the most effective drug ever formally studied for nail or palmoplantar...
Conference Coverage
WCD: IL-23p19 inhibitors yield ‘promising’ psoriasis results
Conference Coverage
WCD: Ixekizumab beats etanercept for psoriatic itch
Key clinical point: Ixekizumab reduces psoriatic itch markedly faster and more profoundly than etanercept. Major finding: Psoriasis patients...
Conference Coverage
VIDEO: Could a deep Koebner phenomenon trigger psoriatic arthritis?
Conference Coverage
Counseling key to guiding rheumatic disease treatment during pregnancy
Conference Coverage
Amgen’s termination of brodalumab stuns psoriasis world
News
Lasting ustekinumab benefits seen in psoriatic arthritis
Key clinical point: The effects of ustekinumab on joint and skin symptoms are maintained for up to 2 years in adult patients with PsA. Major...
Conference Coverage
EULAR: Panel previews updated CVD recommendations
Conference Coverage
Large-scale psoriasis study links trauma to arthritis
Key clinical point: Further research is needed before any clinical recommendations can be made based on these findings.
Conference Coverage
WCD: Psoriasis plus depression magnifies MI risk
Even mild psoriasis plus comorbid depression is associated with a greater risk of acute MI than is either condition alone.
Conference Coverage
Inspiratory muscle training boosts lung function in ankylosing spondylitis
Key clinical point: Inspiratory muscle training combined with conventional muscle rehabilitation boosted pulmonary function in patients with...